Valeria Santini

Valeria Santini

UNVERIFIED PROFILE

Are you Valeria Santini?   Register this Author

Register author
Valeria Santini

Valeria Santini

Publications by authors named "Valeria Santini"

Are you Valeria Santini?   Register this Author

100Publications

2603Reads

39Profile Views

Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.

Crit Rev Oncol Hematol 2019 Aug 25;140:1-7. Epub 2019 May 25.

Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2019.05.013DOI Listing
August 2019

How I treat MDS after hypomethylating agent failure.

Authors:
Valeria Santini

Blood 2019 02 13;133(6):521-529. Epub 2018 Dec 13.

MDS Unit, Hematology, AOU Careggi, University of Florence, Florence, Italy; and Fondazione Italiana Sindromi Mielodisplastiche (FISMonlus), Alessandria, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-03-785915DOI Listing
February 2019

Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes.

Authors:
Valeria Santini

Clin Lymphoma Myeloma Leuk 2018 08 23;18(8):495-500. Epub 2018 May 23.

MDS Unit, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183047
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.05.013DOI Listing
August 2018

Of blood and bone: the sotatercept adventure.

Authors:
Valeria Santini

Lancet Haematol 2018 02 10;5(2):e54-e55. Epub 2018 Jan 10.

MDS Unit, SOD Hematology, AOU Careggi, University of Florence, Florence 50134, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026183000
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(18)30003-6DOI Listing
February 2018

The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.

Clin Lymphoma Myeloma Leuk 2018 02 30;18(2):136-144.e7. Epub 2017 Dec 30.

Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.12.004DOI Listing
February 2018

Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures.

Oncotarget 2018 Feb 24;9(12):10561-10571. Epub 2018 Jan 24.

MDS UNIT, Hematology, AOU-Careggi University Hospital, Department of Experimental and Clinical Medicine, Università degli Studi di Firenze, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.24302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828219PMC
February 2018

Defeating anaemia in myelodysplastic syndromes: another step forward.

Authors:
Valeria Santini

Lancet Oncol 2017 10 1;18(10):1290-1292. Epub 2017 Sep 1.

Department of Hematology, AOU Careggi University of Florence, Florence 50134, Italy. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045173067
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(17)30671-XDOI Listing
October 2017

First-line Therapeutic Strategies for Myelodysplastic Syndromes.

Authors:
Valeria Santini

Clin Lymphoma Myeloma Leuk 2017 07;17S:S31-S36

MDS Unit, Department of Hematology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.02.013DOI Listing
July 2017

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

J Clin Oncol 2017 May 28;35(14):1591-1597. Epub 2017 Mar 28.

Sophie Park, Centre Hospitalier Universitaire (CHU) Grenoble Alpes, Université Grenoble Alpes, Grenoble; Jean-François Hamel and Sylvain Thépot, CHU d'Angers; Sylvain Thépot, Université d'Angers, Institut National de la Santé et de la Recherche Médicale, Unité 1232, and LabEx IGO, Angers; Andrea Toma, CHU Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil; Rosa Sapena and Pierre Fenaux, CHU Saint Louis, AP-HP, Université Paris X; François Dreyfus, CHU Cochin, AP-HP, Université Paris V, Paris; Charikleia Kelaidi, CHU Avicenne, Avicenne; Odile Beyne-Rauzy, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse; Aspasia Stamatoullas, Centre Henri Becquerel, Rouen; Agnès Guerci-Bresler, CHU Nancy, Nancy; Dominique Bordessoule, CHU Dupuytren, Limoges; Pascale Cony-Makhoul, Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy; Stéphane Cheze, CHU de Caen, Caen; Eric Wattel, Centre Hospitalier Lyon-Sud, Pierre Bénite, Lyon; Christian Rose, Université Catholique de Lille, Lille; Norbert Vey, Institut Paoli-Calmettes Marseille, Marseille, France; Maria Diez Campelo, Hospital Universitario de Salamanca, Salamanca; Teresa Bernal, Hospital Central de Asturias, Oviedo; Fernando Ramos, Hospital de León, León; Marisa Calabuig, Hospital Clínico de Valencia; Guillermo F. Sanz, Hospital Universitario y Politecnico La Fe, Valencia, Spain; Valeria Santini and Alessandro Sanna, Azienda Ospedaliero Universitaria (AOU) Careggi and University of Florence, Florence; Enrico Balleari, Istituto di Ricovero e Cura a Carattere Scientifico AOU San Martino di Genova, Genova; Daniela Gioia, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Dario Ferrero, Università degli Studi di Torino; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Torino; Giovanni Cametti, Ospedale Maggiore di Chieri, Chieri; Fabrizio Pane, Università Federico II, Napoli, Italy; Mikkael A. Sekeres and Jaime Fensterl, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Rami Komrokji, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; David P. Steensma, Dana-Farber Cancer Institute, Boston, MA; Gail J. Roboz, Weill Medical College of Cornell University, New York, NY; Jennifer Kaivers and Ulrich Germing, University of Düsseldorf, Düsseldorf; Katharina Götze and Catharina Müller-Thomas, Universität München, München, Germany; and Ioannis Kotsianidis, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3271DOI Listing
May 2017

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).

Leuk Res 2017 Jan 13;52:50-57. Epub 2016 Nov 13.

AOU Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2016.11.008DOI Listing
January 2017

Treatment of low-risk myelodysplastic syndromes.

Authors:
Valeria Santini

Hematology Am Soc Hematol Educ Program 2016 Dec;2016(1):462-469

SODc Hematology, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2016.1.462DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142510PMC
December 2016

Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

J Clin Oncol 2016 09 27;34(25):2988-96. Epub 2016 Jun 27.

Valeria Santini, University of Florence, Florence, Italy; Antonio Almeida, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal; Aristoteles Giagounidis and Stefanie Gröpper, Marien Hospital Düsseldorf; Norbert Gattermann, Heinrich-Heine-Universität, Düsseldorf; Uwe Platzbecker, Technical University Dresden, Dresden, Germany; Anna Jonasova, Charles University General Hospital, Prague, Czech Republic; Norbert Vey, Centre Régional de Lutte Contre le Cancer, Marseille; Pierre Fenaux, Université Paris, Paris, France; Francis Séguy and Albert Hoenekopp, Celgene International, Boudry, Switzerland; Ghulam J. Mufti, King's College Hospital, London, United Kingdom; Rena Buckstein, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Moshe Mittelman and Ron Ram, Tel Aviv University; Ofer Shpilberg, Assuta Medical Center, Tel Aviv, Israel; Consuelo del Cañizo, Hospital Universitario de Salamanca, Salamanca; Alberto Risueño, Celgene Institute for Translational Research Europe, Seville, Spain; Keiya Ozawa, The University of Tokyo, Tokyo, Japan; Kyle J. MacBeth, Celgene Corporation, San Francisco, CA; and Jianhua Zhong and C.L. Beach, Celgene Corporation, Summit, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.0118DOI Listing
September 2016

Anemia as the Main Manifestation of Myelodysplastic Syndromes.

Authors:
Valeria Santini

Semin Hematol 2015 Oct 30;52(4):348-56. Epub 2015 Jun 30.

Hematology, AOU Careggi, University of Florence, Florence, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2015.06.002DOI Listing
October 2015

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.

Authors:
Valeria Santini

Curr Opin Hematol 2015 Mar;22(2):155-62

AOU Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000117DOI Listing
March 2015

On raising the "dust of blood": from unrevealing thrombopoiesis to treatment of thrombocytopenias with thrombomimetic drugs.

Authors:
Valeria Santini

Semin Hematol 2015 Jan 31;52(1):1-3. Epub 2014 Oct 31.

Hematology Unit, University of Florence, Firenze, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2014.10.008DOI Listing
January 2015

Treatment of myelodysplastic syndrome with thrombomimetic drugs.

Semin Hematol 2015 Jan 31;52(1):38-45. Epub 2014 Oct 31.

Service d'Hématologie Séniors, Hôpital St Louis, Assistance Publique, Hôpitaux de Paris, Université Paris 7, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2014.10.005DOI Listing
January 2015

Iron overload and chelation therapy in myelodysplastic syndromes.

Crit Rev Oncol Hematol 2014 Jul 24;91(1):64-73. Epub 2014 Jan 24.

Department of Internal Medicine, Division of Hematology/Oncology, American University of Beirut Medical Center (AUBMC), Beirut, Lebanon. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2014.01.006DOI Listing
July 2014

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Cytometry B Clin Cytom 2014 May 28;86(3):207-15. Epub 2014 Jan 28.

Department of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21160DOI Listing
May 2014

[Identification of myelodysplastic syndromes patients].

Authors:
Valeria Santini

Recenti Prog Med 2014 Mar;105(3):127-31

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1701/1434.15875DOI Listing
March 2014

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Cytometry B Clin Cytom 2014 Jan 15. Epub 2014 Jan 15.

Department of Hematology, VU Institute of Cancer and Immunology (V-ICI), Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cytob.21160DOI Listing
January 2014

Hypomethylating agents and chemotherapy in MDS.

Best Pract Res Clin Haematol 2013 Dec 7;26(4):411-9. Epub 2013 Oct 7.

Hematology, AOU Careggi, University of Florence, Largo Brambilla 3, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2013.09.010DOI Listing
December 2013

Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.

Crit Rev Oncol Hematol 2013 Nov 7;88(2):231-45. Epub 2013 Jul 7.

Haematology unit, University of Florence, Florence, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2013.06.004DOI Listing
November 2013

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.

Haematologica 2013 Sep;98(9):1344-52

Hematology - Bone Marrow Transplantation Center, Fondazione IRCCS Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2013.084020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762089PMC
September 2013

Novel therapeutic strategies: hypomethylating agents and beyond.

Authors:
Valeria Santini

Hematology Am Soc Hematol Educ Program 2012 ;2012:65-73

Department of Hematology, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2012.1.65DOI Listing
June 2013

In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?

Hematology Am Soc Hematol Educ Program 2012 ;2012:74-5

Sylvester Comprehensive Cancer Center, Division of Hematology/Oncology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2012.1.74DOI Listing
June 2013

Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.

Epigenetics 2013 Feb 15;8(2):210-9. Epub 2013 Jan 15.

Dipartimento di Patologia e Oncologia Sperimentali, Università degli Studi di Firenze, Istituto Toscano Tumori, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/epi.23538DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3592907PMC
February 2013

Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells.

Leuk Res 2012 Oct 27;36(10):1290-5. Epub 2012 Jun 27.

UF Ematologia, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.05.023DOI Listing
October 2012

Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins.

Authors:
Valeria Santini

Semin Hematol 2012 Oct;49(4):295-303

University of Florence, AOU Careggi, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2012.09.003DOI Listing
October 2012

Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients.

Clin Cancer Res 2012 Jun 11;18(11):3079-89. Epub 2012 Apr 11.

FU Hematology and Department of Laboratory Medicine, Azienda Ospedaliero Universitaria (AOU) Careggi, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-0686DOI Listing
June 2012

The quest for the perfect MDS scoring system.

Authors:
Valeria Santini

Leuk Res 2012 Feb 10;36(2):125-6. Epub 2011 Dec 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2011.10.026DOI Listing
February 2012

Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.

Authors:
Valeria Santini

Oncologist 2011 ;16 Suppl 3:35-42

Functional Unit of Haematology, AOU Careggi, University of Florence, Largo Brambilla 3, Firenze, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2011-S3-35DOI Listing
January 2012

Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid.

Leuk Res 2011 Jul 5;35(7):921-31. Epub 2011 Mar 5.

Functional Unit of Haematology, Department of Experimental Pathology and Oncology, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126110006
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2011.01.033DOI Listing
July 2011

Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.

Leuk Res 2010 Nov 6;34(11):1410-6. Epub 2010 Jul 6.

Hôpital Avicenne, Assistance Publique, Hôpitaux de Paris and Paris 13 University, Bobigny, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2010.05.021DOI Listing
November 2010

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.

Cancer 2010 Mar;116(6):1485-94

Unit of Hematology and Stem Cell Transplantation, IRCCS, Centro di Riferimento Oncologico della Basilicata, Via Padre Pio 1, 85028 Rionero in Vulture, Potenza, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24894DOI Listing
March 2010

Azacitidine in lower-risk myelodysplastic syndromes.

Authors:
Valeria Santini

Leuk Res 2009 Dec;33 Suppl 2:S22-6

UF Ematologia, Azienda Ospedaliero-Universitaria (AOU) Careggi, Università degli Studi di Firenze, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0145-2126(09)70230-9DOI Listing
December 2009

Is survival enough for myelodysplastic syndromes?

Authors:
Valeria Santini

Leuk Res 2009 Aug 5;33(8):1017-8. Epub 2009 Mar 5.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2009.02.001DOI Listing
August 2009

Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.

Authors:
Valeria Santini

Expert Rev Hematol 2009 Apr;2(2):121-7

UF Ematologia, AOU Careggi, via delle Oblate 1, University of Florence, Florence, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ehm.09.6DOI Listing
April 2009